Potent antihyperglycaemic property of a new imidazoline derivative S-22068 (PMS 847) in a rat model of NIDDM

British Journal of Pharmacology

Volumn 124, Issue 8, 1998, Pages 1591-1596

  Pelé Tounian, Agnès ^a   Wang, Xuan ^a   Rondu, Frédéric ^b   Lamouri, Azzdine ^b   Touboul, Estera ^b   Marc, Sylvie ^c   Dokhan, Raymond ^c   Pfeiffer, Bruno ^d   Manechez, Dominique ^d   Renard, Pierre ^d   Guardiola Lemaître, Béatrice ^d   Godfroid, Jean Jacques ^b   Pénicaud, Luc ^e   Ktorza, Alain ^a,f  

^a EUROPEAN SPACE AGENCY   (France)

^b Laboratoire de Pharmacochimie   (France)

^c LDK France   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^e CNRS   (France)

^f Lab de Physiopathol de la Nutr   (France)

Author keywords

Glucose tolerance; Imidazoline receptors; Imidazolines; Insulin secretion; NIDDM; Plasma glucose; S 22068

Indexed keywords

2 (2 IMIDAZOLIN 2 YL) 1,4 DIISOPROPYLPIPERAZINE; ADRENERGIC RECEPTOR; GLUCOSE; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; INSULIN; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TOLERANCE TEST; HEMODYNAMIC PROCESSES; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR;

EID: 15144353168     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701989     Document Type: Article

References (35)

1. BAILEY, C.J. (1992). Biguanides and NIDDM. Diabetes Care, 15, 755-772.
2. BECK-NIELSEN, H., VAAG, A., DAMSBO, P., HANDBERG, A., NIELSEN, O.H., HENRIKSEN, J.E. & THYE-RONN, P. (1992). Insulin resistance in skeletal muscles in patients with NIDDM. Diabetes care, 15, 418-429.
3. BERDEU, D., PUECH, C., RIBES, G., LOUBATIÈRES-MARIANI, M.-M. & BERTRAND, G. (1997). Antazoline increases insulin secretion and improves glucose tolerance in rats and dogs. Eur. J. Pharmacol., 324, 233-239.
4. BERTRAND, G., GROSS, R., PETIT, P., LOUBATIÈRES-MARIANI, M-M. & RIBES, G. (1992). Evidence for a direct stimulatory effect of cibenzoline on insulin secretion in rats. Eur. J. Pharmacol., 214, 159-163.
5. BRADFORD, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
6. BROADSTONE, V.I., PFEIFFER, M.A., BAJA, V., STRAGNER, J.I. & SAMOIS, E. ( 1987). Alpha-adrenergic blockade improves glucose-potentiated insulin secretion in non-insulin dependent diabetes mellitus, Diabetes, 36, 932-937.
7. BROWN, C.A., CHAN, S.L.F., STILLINGS, M.R., SMITH, S.A. & MORGAN, N.G. (1993). Antagonism of the stimulatory effect of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline, RX801080. Br. J. Pharmacol., 110, 1017-1022.
8. CHAN, S.L.F. & MORGAN, N.G. (1990). Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur. J. Pharmacol., 176, 97-101.
9. ATP channels in insulin-secreting cells. Eur. J. Pharmacol., 204, 41-48.
10. 2-sites. Br. J. Pharmacol., 112, 1065-1070.
11. CONSOLI, A., NURJHAN, N., CAPANI, F. & GERICH, J. (1990). Predominent role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes, 38, 550-557.
12. DE FRONZO, R.A., BONADONNA, R.C. & FERRANNINI E. (1992). Pathogenesis of NIDDM. Diabetes Care, 15, 318-368.
13. 2-adrenoceptors in the human central nervous system. Neuroscience, 59, 589-598.
14. 1-imidazoline sites. J. Pharmacol. Exp. Ther., 264, 172-182.
15. 2 imidazoline receptors in human striatum. Neurochem. Int., 30, 25-29.
16. GERICH, J.E. (1989). Oral hypoglycaemic agents. N. Eng. J. Med., 321, 1231-1245.
17. JUNOD, A., LAMBERT, A.E., ORCI, I., PICTET, R., GONET, A.E. & RENOLD, A.E. (1967). Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med., 126, 201-205.
18. IRWIN, S. (1968). A systematic quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacologia, 13, 222-257.
19. KAWAZU, S., SUZUKI, M., NEGISHI, K., ISHI, J., SANDO, H., KATAGIRI, H., KANAZAWA, Y., YAMANOUCHI, S., AKANUMA, Y., KAJINUMA, H., SUZUKI, K., WATANABE, K., ITOH, T., KOBAYASHI, T. & KOSAKA, K. (1987). Initial phase II clinical studies on midaglizole (DG-5128). Diabetes. 36, 221-226.
20. KRUSZYNSKA, Y.T. & OLEFSKY, J.M. (1996). Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J. Invest. Med., 44, 413-428.
21. LEAHY, J.L. (1990). Natural history of beta cell dysfunction in NIDDM. Diabetes Care, 13, 992-1010.
22. MALLARD, N.J., HUDSON, A.L. & NUTT, D.J. (1992). Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br. J. Pharmacol., 106, 1019-1027.
23. MICHEL, M.C. & ERNSBERGER, P. (1992). Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol. Sci., 13, 369-370.
24. MILLER, R.E. (1981). Pancreatic neuroendocrinology: peripheral neural mechanisms in the regulation of the islets of Langerhans. Endocrinol. Rev., 2, 471-494.
25. 2-imidazoline binding sites. Naunyn. Schmiedebergs Arch. Pharmacol., 351, 507-516.
26. ÖSTENSEN, C.-G., CATTANEO, A.G., DOXEY, J.C. & EFENDIC, S. (1989). α-adrenoceptors and insulin release from pancreatic islets of normal and diabetic rats. Am. J. Physiol., 257, E439-E443.
27. PÉNICAUD, L., FERRE, P., KANDE, J., LETURQUE, A., ISAAD, T. & GIRARD, J. (1987). Effect of anaesthesia on glucose production and utilization in rats. Am. J. Physiol., 252, E365-E369.
28. ROBERTSON, R.P., HALTER, J.B. & PORTE, D. (1976). A role tor alpha-adrenergic receptors in abnormal insulin secretion in Diabetes Mellitus. J. Clin. Invent., 57, 791-795.
29. RONDU, F., LE BIHAN, G., WANG, X., LAMOURI, A., TOUBOUL, E., DIVE, G. BELLAHSENE, T., PFEIFFER, B., RENARD, P., GUARDIOLA-LEMAÎTRE, B., MANECHEZ, D., PÉNICAUD, L., KTORZA, A. & GODFROID, J.-J. (1996). Design and synthesis of imidazoline derivates active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-Benzyl-N′(arylalkyl)-2-(4′,5′-dihydro-1′H-imidazol- 2′yl)piperazines. J. Med. Chem., 40, 3793-3803.
30. SCHENK, J., HEBDEN, A. & MCNEILL, J.H. (1992. Measurement of cardiac left ventricular pressure in conscious rats using a fluid-filled catheter. J. Pharmacol. Toxicol. Methods, 27, 171.
31. SCHULZ, A. & HASSELBLATT, A. (1989). An insulin releasing property of imidazoline derivatives is not limited to compound that block alpha-adrenoceptors. Naunyn Schmied. Arch. Pharmacol., 340, 321-327.
32. TANCREDE, G., ROSSEAU-MIGNERON, S. & NADEAU, A. (1983). Long-term changes in the diabetic state induced by different doses of streptozotocin in rats. Br. J. Exp. Pathol., 64, 117-123.
33. WANG, X., RONDU, F., LAMOURI, A., DOKHAN, R., MARC, S., TOUBOUL, E., PFEIFFER, B., MANECHEZ, D., RENARD, P., GUARDIOLA-LEMAITRE, B, GODFROID J , KTORZA, A. & PÉNICAUD, L, (1996). Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose and insulin secretion in a rat model of type II diabetes. J. Pharmacol. Exp. Ther., 278, 82-89.
34. YOUNGBLOOD, E.B., HENRIKSEN, E.J., JACOB, S., FOGT, D.L. & GÖDIKE, J. (1997). Dose-dependent effect of moxonidine on glucose transport in insulin-resistant rat muscle (abstract). Diabetes (suppl), A372.
35. ZAITSEV, S.V., EFANOV, A.M., FANOVA, I.B., LARSSON, O., OSTENSON, C.-G., GOLD, G., BERGGREN, P.O. & EFENDIC, S. (1996). Imidazoline compounds stimulate insulin release by inhibition of K+-ATP channels and interaction with the exocytotic machinery. Diabetes, 45, 1610-1618.